Microsoft: Fiscal Q4 Earnings Consensus Estimates

Microsoft (NASDAQ: MSFT) will be reporting their fiscal fourth quarter financials on July 27 after markets close. Analysts have a consensus $306.13 12-month price target on the company, via a total of 40 analysts, with 18 analysts having strong buy ratings. 20 analysts meanwhile have buy ratings and two have hold ratings. The street high sits at a $378 price target, and the lowest target sits at $256.70.

23 analysts have revenue estimates for the fourth quarter. The mean revenue estimate between all 23 analysts is $44.243 billion; this number has been revised upwards from $41.9 billion at the start of the year. The highest revenue estimate is $44.869 billion, while the lowest is $43.629 billion.

Onto EBITDA estimates, there are currently only 5 analysts who have fourth-quarter EBITDA estimates. The mean is currently $20.747 billion, with this number having been revised up from $18.474 billion at the start of the year. Street high is $20.915 billion EBITDA estimate and the lowest is $20.229 billion.

Analysts estimate that quarterly earnings per share will come in at $1.92, with this number being revised upwards from $1.71 at the start of the year. Street high is $2.03 and the lowest estimate is $1.81 per share for the quarter.


Information for this briefing was found via Sedar and Refinitiv. The author has no securities or affiliations related to this organization. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security. The author holds no licenses.

Video Articles

Agnico Q1 Earnings Results Overshadowed By A Sinking Gold Price

Why More People Are Starting to Feel Broke | Darrell Thomas – VRIC Media

Newmont Q1 Earnings: A Billion In Free Cash Flow… A Month!

Recommended

Altamira Gold Extends Maria Bonita Porphyry System Westward With 70.6 Metres At 0.51 g/t Hit

Antimony Resources Reports 13.9% Antimony in Latest Drill Core at Bald Hill

Related News

Medipharm Labs Receives Price Target Reduction From Canaccord To $1.75

Yesterday, On November 16th, Medipharm Labs (TSX: LABS) reported their third quarter financial results. Reported...

Tuesday, November 17, 2020, 03:37:00 PM

Columbia Care: Analysts Expect $17.2 Million In Q2 EBITDA

Columbia Care Inc. (CSE: CCHW) announced that they will be reporting their second quarter financials...

Tuesday, August 10, 2021, 11:51:00 AM

Canaccord Slashes Antibe Therapeutics Price Target A Month After Drug Trial Paused

On August 3, Antibe Therapeutics Inc. (TSX: ATE) announced that they have paused their study...

Wednesday, September 29, 2021, 11:44:00 AM

Canaccord Raises Trulieve Price Target To $75 From $60

The last two weeks have been quite an enjoyable time for U.S cannabis sector investors....

Wednesday, January 13, 2021, 02:53:00 PM

Coinbase Sees Canaccord More Than Halve Price Target To $120

On May 10th, Coinbase Global (NASDAQ: COIN) reported its first-quarter financial results, posting $1.165 billion...

Saturday, May 14, 2022, 03:16:00 PM